Login to Your Account



'Highly Emetogenic, Delayed Onset' Key

Can Champ Aloxi Be Toppled In CINV Market? Answer Soon

By Randall Osborne


Monday, November 19, 2007
Among drugs for the consequences of chemo, those with the highest profile are Amgen Inc.'s erythropoietin stimulating agents, Epogen (epoetin alfa) and Aranesp (darbepoetin alfa), and Ortho Biotech Products LP's Procrit (epoetin alfa) - all lately dogged by safety concerns that have led to label changes and lessened reimbursements due to concerns about safety. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription